|
WO2010148411A1
|
|
Method and apparatus for computer modeling hypertension
|
|
AU2009314145A1
|
|
Biomarkers for assessing atherosclerotic potential
|
|
WO2010009278A2
|
|
Interactive system for preparing personalized wellness plans
|
|
EP2223248A1
|
|
Simulating patient-specific outcomes
|
|
WO2008154515A1
|
|
Method and apparatus for modeling rheumatoid arthritis
|
|
SG177948A1
|
|
Method and apparatus for modeling atherosclerosis
|
|
WO2008036680A2
|
|
Reagent sets and gene signatures for non-genotoxic hepatocarcinogenicity
|
|
US2010049492A1
|
|
Method and apparatus for modeling skin sensitization
|
|
EP1999570A2
|
|
Apparatus and method for computer modeling respiratory disease
|
|
US2008120039A1
|
|
Hormone and drug concentrations in the portal vein and hepatic sinusoids
|
|
CA2635720A1
|
|
Systems and methods for remote computer-based analysis of user-provided chemogenomic data
|
|
WO2006099544A2
|
|
Apparatus and method for computer modeling type 1 diabetes
|
|
US2007032420A1
|
|
Treating diabetes with glucagon-like peptide-1 secretagogues
|
|
CA2596816A1
|
|
Method for defining virtual patient populations
|
|
US2007162406A1
|
|
Adjusted sparse linear programming method for classifying multi-dimensional biological data
|
|
AU2005316461A1
|
|
Methods and models for cholesterol metabolism
|
|
WO2006066263A1
|
|
Assessing insulin resistance using biomarkers
|
|
US2006057066A1
|
|
Reagent sets and gene signatures for renal tubule injury
|
|
US2005159357A1
|
|
Treatment of rheumatoid arthritis with soluble Fas-ligand cross-linkers
|
|
US2005158321A1
|
|
Treatment of rheumatoid arthritis with galectin-3 antagonists
|
